Greiner Bio-One
Develops magnetic 3D cell culture technology using biocompatible NanoShuttle-PL nanoparticles to magnetize cells for bioprinting spheroids and structures, enabling high-throughput screening and in-vitro 3D models.
- CEO / Founder
- Ilke Panzer
- Team Size
- 1001-5000
- Stage
- Subsidiary
- Total Funding
- Subsidiary
Technology & Products
Key Products
Greiner Bio-One develops, manufactures, and distributes high-quality plastic laboratory products for clinical diagnostics, life sciences, and biotechnology. Their product solutions are categorized into Preanalytics, BioScience, and Diagnostics divisions.
Technological Advantage
Patented magnetic cell magnetization process (e.g., patents for needle safety devices, though specific bioprinting patents not verified) allows for scalable, high-throughput 3D cell culture with minimal equipment, validated in space applications (Factories in Space project).
Differentiation
Value Proposition
Reduces 3D cell culture setup time from days to hours (15 minutes to a few hours per spheroid) with reproducible, high-throughput formation of spheroids using magnetic bioprinting kits, enhancing drug discovery and biological research efficiency.
How They Differentiate
Uses magnetic bioprinting (no extrusion or inkjet) for faster spheroid formation (15 minutes to hours vs. days for traditional methods) with higher reproducibility and simpler setup compared to competitors' extrusion-based bioprinters.
Market & Competition
Target Customers
Pharmaceutical companies, biotechnology firms, research institutes, universities, hospitals, diagnostic labs
Industry Verticals
Biotechnology; Pharmaceuticals; Medical Research; Diagnostics
Competitors
Organovo; CELLINK; Allevi
Growth & Milestones
Growth Metrics
Revenue reported as €695 million in 2021 (approx $730M USD), with global presence in over 100 countries and 2,300+ employees.
Major Milestones
Acquisition of 3D cell culture technology assets from Nano3D Biosciences; Launch of magnetic 3D bioprinting kits; Validation of bioprinting in space via Factories in Space project; Appointment of Ilke Panzer as CEO in 2024
Notable Customers
National Institutes of Health NCATS